Article

Segment 9: Could the Government Buy Patent Rights for Harvoni?

The idea has been floated that the government should try buying the patent rights for Harvoni from Gilead Sciences in an attempt to improve access, but even if such a move was feasible, no one seems to think it's a good idea.

The idea has been floated that the government should try buying the patent rights for Harvoni from Gilead Sciences in an attempt to improve access, but even if such a move was feasible, no one seems to think it’s a good idea.

“I believe that the government is in the business of governing and should not be a provider of healthcare products,” Ed Cohen, PharmD, FAPhA, said simply.

Matthew D. Harman, PharmD, MPH, and Keith Hoffman, Phd, echoed that belief and wondered how the logistics of such a purchase would work. However, Steven Miller, MD, MBA, after meeting with government committees with jurisdiction over healthcare, is not worried this could happen.

“This idea is going absolutely nowhere,” he said. “This was floated by some people and there is very little enthusiasm for it.”

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Gordon Crofoot, MD, PA
Hamlet Gasoyan, PhD
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
David Awad, PharmD, BCOP
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Ali Khawar
Ali Khawar
Emma Achola-Kothari, PhD
Dr Emma Achola-Kothani
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo